APLS 35.63 (+0.28%)
US03753U1060BiotechnologyBiotechnology

Apellis Pharmaceuticals (APLS) Financial Metrics

This table shows a selected set of financial data points of Apellis Pharmaceuticals (APLS). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 -4.45 0 -13.44 7.1B -0.68 396.59M -595.51M -495.21M -528.63M 351.19M
2022 -6.15 0 -8.41 5.49B -0.79 75.42M -515.27M -584.5M -652.17M 551.8M
2021 -8.84 0 -5.35 3.99B -0.81 66.56M -564.23M -533.01M -746.35M 640.19M
2020 -4.59 0 -12.47 4.3B -0.51 250.65M -165.91M -209.2M -344.87M 565.78M
2019 -4.9 0 -6.25 1.91B -1.03 0 -212.83M -282.84M -304.71M 351.99M
2018 -2.34 0 -5.63 717.49M -0.66 0 -131.24M -124.99M -127.5M 176.27M
2017 -3.68 0 -5.9 301M -0.49 0 -46.6M -50.99M -51.01M 175.64M
2016 -1.51 0 0 0 -0.83 0 -26M -27.12M -27.12M 24.86M
2015 -2.57 0 0 0 -1.77 0 -18.86M -46.52M -46.52M 36M
2014 -0.6 0 0 0 -1.11 0 -9.97M -11.23M -10.79M 13.62M
2013 -0.22 0 0 0 0 0 -3.44M -3.96M -3.96M 4.76M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.